User:Dkhij/sandbox

Dr. Kevin Hay is a Clinician Scientist at the Terry Fox Laboratory and Leukemia/Bone Marrow Transplant Program of BC in Vancouver. Also, he is an Assistant Professor at the University of British Columbia and Medical Director of the Clinical Cell Therapy (CCT) and Conconi Family Immunotherapy Laboratory.

== Education == Dr. Hay received a Bachelor of Science with honours at the Trinity Western University in 2005. After that, he obtained a Master of Science in Immunology at the University of Manitoba (2008), followed by an MD (2011). Then, Dr. Hay completed a medical residency in Internal medicine (2014) and a fellowship in hematology (2016). Dr. Hay was awarded the UBC Clinician Investigator scholarship to pursue a postdoctoral fellowship in cellular immunotherapy, which he completed at the Fred Hutchinson Cancer Research Center in Seattle, Washington, under the mentorship of Dr. Cameron Turtle. == Research and Career == Dr. Hay’s research focuses on understanding the unique toxicities associated with chimeric antigen receptor T (CAR-T) cells, as well as the development of novel CAR-T cell therapies. Dr. Kevin Hay’s lab aims are: (a) develop CAR-T cells targeting other malignancies, such as myeloma, and (b) modify CAR-T cells so as to improve efficacy and decrease toxicity. The lab is focused on multi-antigen targeting approaches, modifications to the CAR construct, and different approaches to T cell manufacturing. With Dr. Robert Holt and Dr. Brad Nelson, Dr. Kevin Hay is a key investigator of the ongoing Canadian Project: Phase I/II Multicenter Clinical Trial of a Novel Single Domain (sd)CD-22-specific Camelid-derived Chimeric Antigen Receptor (CAR) T-cell Therapy. Also, Dr. Hay is one of the members of the group conducting the first trial that uses Canadian-made CAR T cells. This first-of-its-kind clinical trial in Canada involves manufacturing and administering a CLIC-1901 cell therapy, which could add to current treatments available to the thousands of Canadians diagnosed with ALL and NHL each year. Under the direction of Dr. Kevin Hay, the CCT Laboratory continues to play a key role in facilitating the design and implementation of new therapies for patients in the Leukemia/BMT Program of BC. Currently, the staff is involved in several new protocols, including CAR T-cell infusions and the processing of serum eyedrops for patients with chronic graft-versus-host disease.

=== References ===